{
    "clinical_study": {
        "@rank": "79010", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Intervention", 
                "arm_group_type": "Active Comparator", 
                "description": "Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day."
            }
        ], 
        "brief_summary": {
            "textblock": "Glucocorticoids therapy exposes the patient to an increased risk for diabetes morbidity.\n      However, there is no proven preventive therapy. GLP-1-RA has shown to improve glucose\n      metabolism in healthy volunteers treated with glucocorticoids. We assume that GLP-1-RA will\n      improve glucose metabolism in patients with high risk for diabetes morbidity, treated  with\n      glucocorticoids."
        }, 
        "brief_title": "Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes", 
        "condition": "Glucocorticoid Induced Hyperglycemia", 
        "condition_browse": {
            "mesh_term": "Hyperglycemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Planned treatment with T. Prednisone in dosage >0.5 mg/kg for two weeks or more.\n\n          -  Age >18 years\n\n          -  Body mass index >27 kg/m2 OR 1st degree relative with type 2 diabetes mellitus OR\n             hypertension OR hyperlipidemia OR gestational diabetes in the past OR diagnosis of\n             polycystic ovary syndrome.\n\n        Exclusion criteria:\n\n          -  Glycosylated hemoglobin A1c >6.5%\n\n          -  Diagnosis of diabetes mellitus or treatment with anti-glycemic drug\n\n          -  Pancreatitis (acute or chronic) in the past\n\n          -  Active malignancy\n\n          -  Medullary thyroid carcinoma or multiple endocrine neoplasm type 2 of the patient or\n             of 1st degree relative\n\n          -  Pregnancy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016846", 
            "org_study_id": "0209-13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intervention", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Glucocorticoids"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 22, 2013", 
        "location": {
            "contact": {
                "email": "tiroshamit@gmail.com", 
                "last_name": "Amit Tirosh, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Petah Tiqva", 
                    "country": "Israel"
                }, 
                "name": "Rabin Medical Center, Beilinson Campus"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "tiroshamit@gmail.com", 
            "last_name": "Amit Tirosh, MD", 
            "phone": "+972.50.8191078"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Clalit Health Services"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Glucose levels 2 hours after 75 gr OGTT", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016846"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Rabin Medical Center", 
            "investigator_full_name": "Amit Tirosh", 
            "investigator_title": "Dr", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Rabin Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rabin Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}